International (English)
Locale
Play Video

The Pioneer and Leader in New Acute Care Blood Purification

“Over the past decade we have worked tirelessly to help save the lives of patients worldwide with our CytoSorb® Therapy. We are proud to work with our healthcare partners to bring this vital therapy to patients in need and we are excited about the future opportunity to continue to help save lives.”

Dr. Phillip Chan, Chief Executive Officer of CytoSorbents

0
Treatments
0
Treatments Published
0
Patient Cases Published

CytoSorb® Therapy

Safe and easy to use

About

The CytoSorb® Therapy* is based on an extracorporeal blood purification procedure that was shown to effectively reduce excessive levels of inflammatory mediators. This is intended to alleviate the excess systemic inflammatory associated with systemic hyperinflammation or septic shock. Thus, the life-threatening complications of a cytokine storm can potentially be avoided and, above all, the stabilization of hemodynamics promoted.The CytoSorb® Therapy is an adjunctive therapy. The principles of causal and supportive therapy, such as dealing with the focal source and early anti-infective therapy, of course, retain their outstanding importance even under CytoSorb® Therapy.

Safety

CytoSorb® Therapy has been used more than 200,000 times worldwide in more than 1,000 clinical departments, and its application has been proven to be well-tolerated and safe.

The CytoSorb® adsorber can be used for up to 24 hours after which a change is necessary if the treatment indication persists. Patients have been treated for up to seven consecutive days, for 24 hour periods.

Easy to use

The adsorber is a standard whole blood cartridge and can be used with conventional dialysis and hemofiltration equipment, as well as heart-lung machines, extracorporeal life support machines, or as a stand-alone therapy with blood pumps in hemoperfusion mode. The treatment can be prepared after a short training and can be easily integrated into routine procedures

Clinical Evidence

Evolution

CytoSorb® has 347 peer reviewed published articles in the last 10years* versus 124 for comparable technologies combined

* 01/2012 – 12/2021 pre-clinical and clinical data

Literature Database

Your source of information for CytoSorb® Therapy

Distribution

in +70 countries

Voices

From around the world

Play Video

Dr. Gabriella Bottari, Italy
Children´s Hospital Bambino Gesù

Play Video

Dr. Yatin Mehta, India
Medanta Hospital Gurgaon

Play Video

Prof. Can Ince, The Netherlands
Erasmus Medical Center Rotterdam

Play Video

Mauro Atti, Italy
Aferetica

Play Video

Dr. Moritz Fischer, Germany
Fresenius Medical Care

Play Video

Dr.Tobias Hübner, Schwitzerland
Müsterlinger Cantonal Hospital

Play Video

Prof. Federico Pappalardo, Italy
National Hospital Alessandria

#10yrsCytoSorbTherapy

Celebrate with us

10Years CytoSorb Therapy

CytoSorbents Europe GmbH
Müggelseedamm 131
12587 Berlin

support(at)cytosorbents.com

©2022 CYTOSORBENTS EUROPE GMBH | ALL RIGHTS RESERVED

*Cytosorb Therapy is the use of the CytoSorb adsorber in conditions where elevated levels of Cytokines and/or Bilirubin and/or Myoglobin exist. CytoSorb can also be used intraoperatively for the removal of Ticagrelor and/or Rivaroxaban during Cardiopulmonary-Bypass.

This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.